Índice

• • ·Chasing the greenback and the decline in scientific rigour

    Página :433

     
• • ·Treatment of brain metastases in patients with melanoma

    Página :434-435

    Rosalie Fisher, James Larkin

     
• • ·Is benefit of maintenance therapy for NSCLC best defined by progression-free survival?

    Página :435-436

    Karen L Reckamp

     
• • ·Oestrogen and breast cancer: results from the WHI trial

    Página :437-438

    Anthony Howell, Jack Cuzick

     
• • ·Screening for anal cancer: endpoints needed

    Página :438-440

    Nicolas Wentzensen

     
• • ·Intensifying tumour immunity through combination therapy

    Página :440-442

    Glenn Dranoff

     
• • ·A new generation of EGFR tyrosine-kinase inhibitors in NSCLC

    Página :442-443

    Fred R Hirsch, Paul A Bunn

     
• • ·The STAMPEDE trial and celecoxib: how to adapt?

    Página :443-445

    Andrew J Armstrong

     
• • ·Integration of palliative and supportive cancer care in Asia

    Página :445-446

    Jacqueline J Chin, Calvin W Ho, Hitoshi Arima, Reina Ozeki, Dae-Seog Heo, Michael K Gusmano, Nancy Berlinger

    
• • ·Revolutionising cancer care in South Africa

    Página :447-448

    Leon Gouws, David Eedes, Ernst Marais, Praneet Valodia, Martin De Villiers

     
• • ·Personalised medicine in oncology: questions for the next 20 years

    Página :448-449

    Jean-Yves Blay, Denis Lacombe, Françoise Meunier, Roger Stupp

     
• • ·Errata

    Página :e186

    
• • ·Errata

    Página :e186

    
• • ·Overcoming resistance of cancer stem cells

    Página :e187

    Diana Pignalosa, Marco Durante

     
• • ·Placebo effect in hot flush research

    Página :e188

    Suzanne M Mahon, Marcelle Kaplan

    
• • ·Endometriosis and ovarian cancer

    Página :e188

    Paolo Vercellini, Edgardo Somigliana, Laura Buggio, Giorgio Bolis, Luigi Fedele

    
• • ·Endometriosis and ovarian cancer

    Página :e189

    Sun-Wei Guo, Marya D Zilberberg, Lone Hummelshoj

     
• • ·Endometriosis and ovarian cancer – Authors’ reply

    Página :e190

    Celeste Leigh Pearce, Andrew Berchuck

    
• • ·States and US Government spar over medical marijuana

    Página :450

    Bryant Furlow

    
• • ·BRICS nations tackle non-communicable diseases

    Página :451

    Talha Khan Burki

     
• • ·Global science funding in a tail spin?

    Página :452

    Kathryn Senior

     
• • ·65th Cancer Symposium of the Society of Surgical Oncology

    Página :453

    Lan-Lan Smith

    Esquema Esquema  
• • ·AACR annual meeting 2012

    Página :454

    Malini Guha

    Esquema Esquema  
• • ·New report sets guidelines for omics research

    Página :e191

    Norra MacReady

     
• • ·Mutational analysis in AML aids risk stratification

    Página :e191

    Vicki Brower

    
• • ·No survival benefit of olaparib in ovarian cancer patients

    Página :e192

    Neil Bennet

    
• • ·A new option for relapsed or refractory Hodgkin’s lymphoma

    Página :e192

    Sharan Prakash Sharma

    
• • ·Fukushima: 1-year on

    Página :e193

    Talha Khan Burki

     
• • ·Expensive US cancer care: value for money?

    Página :e193

    Bryant Furlow

    
• • ·CRUK: funding policy under scrutiny

    Página :e194

    Kathryn Senior

     
• • ·Will plain packaging spell the end of tobacco marketing?

    Página :e195

    Tony Kirby

     
• • ·Heterogeneity of induction failure in childhood ALL

    Página :e195

    Neil Bennet

    
• • ·Endangered species and cancer: protecting Noah’s Ark

    Página :455

    Tim Dehnel

     
• • ·Telecommunications in skin cancer prevention and diagnosis

    Página :456

    Li Shum

    
• • ·Coffee: the science and art of moderation

    Página :457-458

    Jonathan Krell, Justin Stebbing

      
• • ·A Monster Calls

    Página :458

    Odhran O’Donoghue

     
• • ·Voices from the front: May

    Página :458

    David M Mastrianni

    
• • ·Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

    Página :459-465

    Kim Margolin, Marc S Ernstoff, Omid Hamid, Donald Lawrence, David McDermott, Igor Puzanov, Jedd D Wolchok, Joseph I Clark, Mario Sznol, Theodore F Logan, Jon Richards, Tracy Michener, Agnes Balogh, Kevin N Heller, F Stephen Hodi

    Resumen Resumen Esquema Esquema  
• • ·Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

    Página :466-475

    Li Zhang, Shenglin Ma, Xiangqun Song, Baohui Han, Ying Cheng, Cheng Huang, Shujun Yang, Xiaoqing Liu, Yunpeng Liu, Shun Lu, Jie Wang, Shucai Zhang, Caicun Zhou, Xiangwei Zhang, Nobuya Hayashi, Mengzhao Wang, on behalf of the INFORM investigators ‡

    Resumen Resumen Esquema Esquema   
• • ·Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial

    Página :476-486

    Garnet L Anderson, Rowan T Chlebowski, Aaron K Aragaki, Lewis H Kuller, JoAnn E Manson, Margery Gass, Elizabeth Bluhm, Stephanie Connelly, F Allan Hubbell, Dorothy Lane, Lisa Martin, Judith Ockene, Thomas Rohan, Robert Schenken, Jean Wactawski-Wende

    Resumen Resumen Esquema Esquema  
• • ·Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis

    Página :487-500

    Dorothy A Machalek, Mary Poynten, Fengyi Jin, Christopher K Fairley, Annabelle Farnsworth, Suzanne M Garland, Richard J Hillman, Kathy Petoumenos, Jennifer Roberts, Sepehr N Tabrizi, David J Templeton, Andrew E Grulich

    Resumen Resumen Esquema Esquema   
• • ·Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

    Página :501-508

    Ravi A Madan, Mahsa Mohebtash, Philip M Arlen, Matteo Vergati, Myrna Rauckhorst, Seth M Steinberg, Kwong Y Tsang, Diane J Poole, Howard L Parnes, John J Wright, William L Dahut, Jeffrey Schlom, James L Gulley

    Resumen Resumen Esquema Esquema   
• • ·Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

    Página :509-517

    Alfons JM van den Eertwegh, Jurjen Versluis, H Pieter van den Berg, Saskia JAM Santegoets, R Jeroen A van Moorselaar, Tim M van der Sluis, Helen E Gall, Thomas C Harding, Karin Jooss, Israel Lowy, Herbert M Pinedo, Rik J Scheper, Anita GM Stam, B Mary E von Blomberg, Tanja D de Gruijl, Kristen Hege, Natalie Sacks, Winald R Gerritsen

    Resumen Resumen Esquema Esquema   
• • ·Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials

    Página :518-527

    Annemijn M Algra, Peter M Rothwell

    Resumen Resumen Esquema Esquema   
• • ·Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

    Página :528-538

    Vincent A Miller, Vera Hirsh, Jacques Cadranel, Yuh-Min Chen, Keunchil Park, Sang-We Kim, Caicun Zhou, Wu-Chou Su, Mengzhao Wang, Yan Sun, Dae Seog Heo, Lucio Crino, Eng-Huat Tan, Tsu-Yi Chao, Mehdi Shahidi, Xiuyu Julie Cong, Robert M Lorence, James Chih-Hsin Yang

    Resumen Resumen Esquema Esquema   
• • ·Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

    Página :539-548

    James Chih-Hsin Yang, Jin-Yuan Shih, Wu-Chou Su, Te-Chun Hsia, Chun-Ming Tsai, Sai-Hong Ignatius Ou, Chung-Jen Yu, Gee-Chen Chang, Ching-Liang Ho, Lecia V Sequist, Arkadiusz Z Dudek, Mehdi Shahidi, Xiuyu Julie Cong, Robert M Lorence, Pan-Chyr Yang, Vincent A Miller

    Resumen Resumen Esquema Esquema   
• • ·Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial

    Página :549-558

    Nicholas D James, Matthew R Sydes, Malcolm D Mason, Noel W Clarke, John Anderson, David P Dearnaley, John Dwyer, Gordana Jovic, Alastair WS Ritchie, J Martin Russell, Karen Sanders, George N Thalmann, Gianfilippo Bertelli, Alison J Birtle, Joe M O’Sullivan, Andrew Protheroe, Denise Sheehan, Narayanan Srihari, Mahesh KB Parmar, for the STAMPEDE investigators

    Resumen Resumen Esquema Esquema   
• • ·Phase 2 trial design in neuro-oncology revisited: a report from the RANO group

    Página :e196

    Evanthia Galanis, Wenting Wu, Timothy Cloughesy, Kathleen Lamborn, Bhupinder Mann, Patrick Y Wen, David A Reardon, Wolfgang Wick, David Macdonald, Terri S Armstrong, Michael Weller, Michael Vogelbaum, Howard Colman, Daniel J Sargent, Martin J van den Bent, Mark Gilbert, Susan Chang

    Resumen Resumen Esquema Esquema  
• • ·Melanoma molecular classes and prognosis in the postgenomic era

    Página :e205

    Elisa Tremante, Agnese Ginebri, Elisa Lo Monaco, Pasquale Frascione, Franco Di Filippo, Irene Terrenato, Maria Benevolo, Marcella Mottolese, Edoardo Pescarmona, Paolo Visca, Pier Giorgio Natali, Patrizio Giacomini

    Resumen Resumen Esquema Esquema   
• • ·Nodal-staging surgery for locally advanced cervical cancer in the era of PET

    Página :e212

    Sebastien Gouy, Philippe Morice, Fabrice Narducci, Catherine Uzan, Jennifer Gilmore, Hélène Kolesnikov-Gauthier, Denis Querleu, Christine Haie-Meder, Eric Leblanc

    Resumen Resumen Esquema Esquema  
• • ·Mediastinal staging of lung cancer: novel concepts

    Página :e221

    Kurt G Tournoy, Steven M Keller, Jouke T Annema

    Resumen Resumen Esquema Esquema